Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies

Drug Safety

Volumn 37, Issue 7, 2014, Pages 501-520

  Trifiró, Gianluca ^a   Sultana, Janet ^a   Spina, Edoardo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BEHAVIOR; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; FEMUR FRACTURE; HEART ARRHYTHMIA; HIP FRACTURE; HUMAN; HYPERGLYCEMIA; LANGUAGE; MORTALITY; OBSERVATIONAL STUDY; PATIENT SAFETY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; DRUG USE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PRESCRIPTION; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; DEMENTIA; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; OBSERVATIONAL STUDY AS TOPIC;

EID: 84904728420     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0170-y     Document Type: Review

References (126)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-7. (Pubitemid 41797645)
2. Burns A, Iliffe S. Dementia. BMJ. 2009;338:b75.
3. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011;10(1):35-43.
4. Testad I, Aasland AM, Aarsland D. The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. Int J Geriatr Psychiatry. 2005;20(6):587-90. (Pubitemid 40873352)
5. Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes: a 12-month follow-up study. Am J Geriatr Psychiatry. 2008;16(7):528-36.
6. Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113(6):429-34. (Pubitemid 20333450)
7. Rosdinom R, Zarina MZ, Zanariah MS, Marhani M, Suzaily W. Behavioural and psychological symptoms of dementia, cognitive impairment and caregiver burden in patients with dementia. Prev Med. 2013;57 Suppl:S67-9
8. Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer's disease. Curr Treat Options Neurol. 2012;14(2):113-25.
9. Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol. 2008;6(2):117-24. (Pubitemid 352024796)
10. Factor SA. Pharmacology of atypical antipsychotics. Clin Neuropharmacol. 2002;25(3):153-7. (Pubitemid 34556424)
11. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65.-73.
12. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-9. (Pubitemid 34680462)
13. Stahl S. Antipsychotic agents. In: Stahl SM, editor. Stahl's essential psychopharmacology. 4th ed. New York: Cambridge University Press;2013.
14. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64(9):1106-12. (Pubitemid 37158258)
15. Trifiro G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol. 2005;61(1):47-53. (Pubitemid 40558279)
16. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
17. Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213-8. (Pubitemid 46933366)
18. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-38. (Pubitemid 44547805)
19. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-69.
20. Barnes TR, Banerjee S, Collins N, Treloar A, McIntyre SM, Paton C. Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry. 2012;201(3):221-6.
21. Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res. 2009;59:1-12.
22. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438-46.
23. Trifiro G, Sini G, Sturkenboom MC, Vanacore N, Mazzaglia G, Caputi AP, et al. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia. Int Clin Psychopharmacol. 2010;25(1):22-8.
24. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96-103.
25. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68(2):190-7.
26. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev. 2006;7(6):492-500. (Pubitemid 44012289)
27. National Institute of Health and Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. 2006 (cited 16 Apr 14). Available from: http://pathways.nice.org.uk/pathways/dementia#path= view%3A/pathways/dementia/dementia-interventions.xml&content= view-node%3Anodes-pharmacological-interventions-for-non-cognitive-symptoms.
28. Pollock B, Forsyth C, Bies R. The critical role of clinical pharmacology in geriatric psychopharmacology. Clin Pharmacol Ther. 2009;85(1):89-93.
29. Trifiro G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12(7):611-20.
30. A roadmap to key pharmacologic principles in using antipsychotics. Prim Care Companion J Clin Psychiatry. 2007;9(6):444-54.
31. US FDA. Public Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. Available from: http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm053171. htm.
32. European Medicines Agency. EMEA public statement on the safety of olanzapine (Zyprexa, Zyprexa Velotab). 2004 (cited 18 Sep 2013). Available from: http://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/ Service/aktuelles/emea-zyprexa-st.pdf?-blob=publicationFile&v=2.
33. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Jama. 2005;294(15):1934-43. (Pubitemid 41464695)
34. US FDA. Information on conventional antipsychotics. 2008. Available from: http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm107211.htm.
35. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-41. (Pubitemid 41713745)
36. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-32. (Pubitemid 46426056)
37. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568-76;quiz 623.
38. US FDA. Information for healthcare professionals: conventional antipsychotics. 2008 (cited 19 Sep 2013). Available from: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm124830.htm.
39. Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry. 2007;15(11):932-41.
40. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-86. (Pubitemid 351650498)
41. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977.
42. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-9.
43. Sultana J, Chang CK, Hayes RD, Broadbent M, Stewart R, Corbett A, et al. Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study. Int J Geriat Psychiatry. Epub 14 Mar 2014.
44. Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340-7.
45. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66(9):1090-6. (Pubitemid 41442273)
46. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):E411-9.
47. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005;107(6):497-508. (Pubitemid 41395226)
48. Hollis J, Forrester L, Brodaty H, Touyz S, Cumming R, Grayson D. Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Aust N Z J Psychiatry. 2007;41(9):751-8. (Pubitemid 47261154)
49. Aparasu RR, Chatterjee S, Mehta S, Chen H. Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents. Med Care. 2012;50(11):961-9.
50. Setoguchi S, Wang PS, Alan Brookhart M, Canning CF, Kaci L, Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc. 2008;56(9):1644-50.
51. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007;15(5):416-24.
52. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr. 2005;17(3):429-41. (Pubitemid 41391687)
53. Janssen-Ortho. Risperdal (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials [Dear Healthcare Professional Letter]. Toronto: Janssen-Ortho Inc.; 2000. Available from: http://www.hc-sc.gc.ca/hpb- dgps/therapeut/zfiles/english/advisory/industry/risperdal1-e.pdf2002.
54. Committee on Safety of Medicines. Latest news: atypical antipsychotic drugs and stroke. 2004 (Cited 15 May 14). Available from: http://www.mhra.gov. uk/Safetyinformation/Safetywarningsalertsandrecalls/ Safetywarningsandmessagesformedicines/CON1004298.
55. Italian Drug Agency.Nota informativa importante concordata conle autorità regolatorie europee e l'AIFA. Abilify (aripiprazolo). 2005 (Cited 15 May 14). Accessed from: http://www.agenziafarmaco.gov.it/wscs-render- attachment-by-id/111.42951.11587699323687791.pdf?id=111.98244.1138874026036.
56. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113-5. (Pubitemid 38736000)
57. Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17(4):617-29. (Pubitemid 41758766)
58. Percudani M, Barbui C, Fortino I, Tansella M, Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol. 2005;25(5):468-70. (Pubitemid 41368370)
59. Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27(6):595-601. (Pubitemid 351339446)
60. Sacchetti E, Trifiro G, Caputi A, Turrina C, Spina E, Cricelli C, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol. 2008;22(1):39-46.
61. Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19(5):473-82. (Pubitemid 41392301)
62. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):445.
63. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134-43. (Pubitemid 36268315)
64. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170(9):1395. (Pubitemid 38594631)
65. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
66. Wu CS, Wang SC, Gau SS, Tsai HJ, Cheng YC. Association of stroke with the receptor-binding profiles of antipsychotics: a case-crossover study. Biol Psychiatry. 2013;73(5):414-21.
67. Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012;60(3):420-9.
68. Wang PS, Schneeweiss S, Setoguchi S, Patrick A, Avorn J, Mogun H, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27(6):707-10. (Pubitemid 351339462)
69. Laredo L, Vargas E, Blasco AJ, Aguilar MD, Moreno A, Portoles A. Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study. J Am Geriatr Soc. 2011;59(7):1182-7.
70. Wang S, Linkletter C, Dore D, Mor V, Buka S, Maclure M. Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. Stroke. 2013;43(1):28-31.
71. Chan MC, Chong CS, Wu AY, Wong KC, Dunn EL, Tang OW, et al. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. Int J Geriat Psychiatry. 2010;25(4):362-70.
72. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909-14.
73. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91-103. (Pubitemid 40321762)
74. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc. 2004;5(2):129-32. (Pubitemid 38380415)
75. Wallaschofski H, Lohmann T, Hild E, Kobsar A, Siegemund A, Spilcke-Liss E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost. 2006;96(1):38-44. (Pubitemid 44160869)
76. Knol W, van Marum R, Jansen P, Souverein P, Schobben A, Egberts A. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc Sci Med. 2008;56:661-6. (Pubitemid 351473519)
77. Trifiro G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418-25, W139-40.
78. Trifiro G. Antipsychotic drug use and community-acquired pneumonia. Curr Infect Dis Rep. 2011;13(3):262-8.
79. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, t Jong GW, Kingma JH, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164(12):1293-7. (Pubitemid 38828879)
80. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048-52. (Pubitemid 30162807)
81. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011;25(6):473-90.
82. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58(12):1161-7. (Pubitemid 33121508)
83. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325(7372):1070.
84. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-35.
85. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry. 2002;180:515-22. (Pubitemid 34596802)
86. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900-6.
87. Narang P, El-Refai M, Parlapalli R, Danilov L, Manda S, Kaur G, et al. Antipsychotic drugs: sudden cardiac death among elderly patients. Psychiatry (Edgmont). 2010;7(10):25-9.
88. Medicines and Health products Regulatory Agency. MHRA public assessment report: the risk of venous thromboembolism associated with antipsychotics. 2009.
89. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000;356(9237):1219-23.
90. Tipper R, Hare E, Kondracki S, Taikato M, Lawrie SM. Antipsychotic drugs and venous thromboembolism. Lancet. 2001;357(9253):391;author reply, 2.
91. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet. 2000;356(9225):252.
92. Ray J, Mamdani M, Yeo E. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost. 2002;88(2):205-9. (Pubitemid 34873699)
93. Parkin L, Skegg DC, Herbison GP, Paul C. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf. 2003;12(8):647-52. (Pubitemid 38028778)
94. Kamijo Y, Soma K, Nagai T, Kurihara K, Ohwada T. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J. 2003;67(1):46-8. (Pubitemid 36119621)
95. Hamanaka S, Kamijo Y, Nagai T, Kurihara K, Tanaka K, Soma K, et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J. 2004;68(9):850-2. (Pubitemid 39243806)
96. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165(22):2677-82. (Pubitemid 41785068)
97. Lacut K, Le Gal G, Couturaud F, Cornily G, Leroyer C, Mottier D, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol. 2007;21(6):643-50. (Pubitemid 350151244)
98. Hagg S, Bate A, Stahl M, Spigset O. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf. 2008;31(8):685-94. (Pubitemid 352019566)
99. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med. 1992;152(8):1660-4.
100. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245.
101. Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. J Clin Psychopharmacol. 2013;33(6):753-8.
102. Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol. 2012;35(3):141-7.
103. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93. (Pubitemid 40677047)
104. Rondanelli M, Sarra S, Antoniello N, Mansi S, Govoni S, Falfo F. No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease. Minerva Med. 2006;97:147-51. (Pubitemid 43966273)
105. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166(5):583-90.
106. Lipscombe LL, Levesque L, Gruneir A, Fischer HD, Juurlink DN, Gill SS, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med. 2009;169(14):1282-9.
107. Rafaniello C, Lombardo F, Ferrajolo C, Sportiello L, Parretta E, Formica R, et al. Predictors of mortality in atypical antipsy-chotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy. Eur J Clin Pharmacol. 2014;70(2):187-95.
108. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(1):10-28.
109. Trifiro G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf. 2007;16(5):538-44. (Pubitemid 46824275)
110. Shin JY, Choi NK, Jung SY, Lee J, Kwon JS, Park BJ. Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study. J Psychopharmacol. 2013;27(7):638-44.
111. Hatta K, Kishi Y, Wada K, Odawara T, Takeuchi T, Shiganami T, et al. Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients: a prospective observational study. Int J Geriat Psychiatry. 2013.
112. Liperoti R, Onder G, Lapane KL, Mor V, Friedman JH, Bernabei R, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry. 2007;68(6):929-34. (Pubitemid 47015494)
113. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2009;20(9):1499-506.
114. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874.
115. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. (Pubitemid 43797117)
116. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-22.
117. Schneeweiss S, Glynn R, Tsai E, Avorn J, Solomon D. Assessment of bias by unmeasured confounders in pharmacoepidemiologic claims data studies using external data. Epidemiology. 2005;16:17-24. (Pubitemid 40239274)
118. Nonino F, De Girolamo G, Gamberini L, Goldoni CA. Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study. Neurol Sci. 2006;27(6):375-80. (Pubitemid 46062650)
119. Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, et al. Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;31(3):218-24.
120. Liu ME, Tsai SJ, Chang WC, Hsu CH, Lu T, Hung KS, et al. Population-based 5-year follow-up study in Taiwan of dementia and risk of stroke. PloS ONE. 2013;8(4):e61771.
121. Gau JT, Acharya U, Khan S, Heh V, Mody L, Kao TC. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr. 2010;10:45.
122. Star K, Bate A, Meyboom RH, Edwards IR. Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Br J Gen Pract. 2010;60(579):e385-94.
123. Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):217-25. (Pubitemid 44436834)
124. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010;11(2):120-7.
125. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf. 2011;34(7):567-75.
126. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001;158(6):892-8. (Pubitemid 32547618)